VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Virax Biolabs Group Ltd
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026
$1.40−0.05 (-3.45%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2020 to 2026
Gross margin
61.9%+69.5 pts over 5 years
Operating margin
-51515.2%−50994.6 pts over 5 years
Net margin
-40439.1%−39913.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +96.2% | +13.2% | -36.9% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -75.7% | |
| Return on assets | – | – | -68.1% | |
| Current ratio | – | 0.05 | 9.97 | |
| Inventory turnover | – | – | 0.1× | |
| Capex to revenue | – | – | 2059.3% | |
| Diluted shares | – | 0M | 0M |
Cash use needs five years of cash flow figures
Virax Biolabs does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-40439.1%
×Asset turnover0.00×
×Equity multiplier1.11×
=Return on equity, FY2026-75.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -40439.1% | 0.00× | 1.11× | -75.7% |
| FY2025 | -95739.2% | 0.00× | 1.08× | -109.6% |
| FY2024 | -4304.8% | 0.02× | 1.06× | -92.9% |
| FY2023 | -63748.3% | 0.00× | 1.21× | -133.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
5of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$5.02M
- Cash generatingOperating cash flow above zero-$4.62M
- Return on assets improvedROA up on the prior year-110.5% → -78.2%
- Earnings backed by cashOperating cash flow above net income-$4.62M vs -$5.02M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.27 → 9.97
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year-838.21% → 61.90%
- More efficientAsset turnover rose0.00 → 0.00